India Pharma Outlook Team | Friday, 20 November 2026
Natco Pharma has secured VAI status from the USFDA following an inspection of its Finished Dosage Formulations manufacturing facility in Visakhapatnam, Andhra Pradesh.
The regulatory outcome comes despite four observations that the US regulator issued through Form 483 after inspecting the facility in August 2026.
The Establishment Inspection Report confirms the inspection classification as Voluntary Action Indicated (VAI).
This development gives Natco Pharma greater clarity on the inspection outcome while highlighting the need for continued manufacturing quality improvements and regulatory compliance.
Form-483 Observations: The USFDA issued four observations after identifying conditions that may require corrective measures during the facility inspection.
EIR Confirmation: The Establishment Inspection Report confirmed the final inspection assessment and VAI classification for the facility.
VAI Status: Voluntary Action Indicated means the FDA does not recommend regulatory action at present, but expects the company to address the observations through appropriate corrective measures.
The USFDA inspected Natco Pharma's FDF manufacturing facility in Visakhapatnam, between August 17 and August 21, 2026. Following the inspection, the regulator issued four observations through Form 483. The VAI outcome therefore provides a clearer picture of the inspection's regulatory implications rather than indicating an entirely observation-free inspection.
Also Read: Moving Indian Pharma from Volume to Value Through Innovation and Strategic Partnerships
The EIR and VAI status mark an important regulatory development for Natco Pharma as it continues its pharmaceutical manufacturing and international business operations.
The company develops, manufactures, and distributes generic and branded pharmaceuticals, specialty medicines, and active pharmaceutical ingredients (APIs). Its business also includes a focus on limited-competition molecules in the US market, making regulatory compliance important for its international operations.
Natco Pharma's next priority will involve addressing the four observations and strengthening its manufacturing quality systems. The company must continue to focus on:
The VAI status offers a favorable regulatory outcome, but continued compliance and effective corrective measures will remain important for Natco Pharma's US market operations.